Literature DB >> 30818002

Cancer cells stemness: A doorstep to targeted therapy.

Sahdeo Prasad1, Sharavan Ramachandran1, Nehal Gupta1, Itishree Kaushik1, Sanjay K Srivastava2.   

Abstract

Recent advances in research on cancer have led to understand the pathogenesis of cancer and development of new anticancer drugs. Despite of these advancements, many tumors have been found to recur, undergo metastasis and develop resistance to therapy. Accumulated evidences suggest that small population of cancer cells known as cancer stem cells (CSC) are responsible for reconstitution and propagation of the disease. CSCs possess the ability to self-renew, differentiate and proliferate like normal stem cells. CSCs also appear to have resistance to anti-cancer therapies and subsequent relapse. The underlying stemness properties of the CSCs are reliant on multiple molecular targets such as signaling pathways, cell surface molecules, tumor microenvironment, apoptotic pathways, microRNA, stem cell differentiation, and drug resistance markers. Thus an effective therapeutic strategy relies on targeting CSCs to overcome the possible tumor relapse and chemoresistance. The targeted inhibition of these stem cell biomarkers is one of the promising approaches to eliminate cancer stemness. This review article summarizes possible targets of cancer cell stemness for the complete treatment of cancer.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Cancer stem cells; Chemoresistance; Metastasis; Molecular targets; Tumor relapse

Year:  2019        PMID: 30818002     DOI: 10.1016/j.bbadis.2019.02.019

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  37 in total

Review 1.  Resistin: An inflammatory cytokine with multi-faceted roles in cancer.

Authors:  Sarabjeet Kour Sudan; Sachin Kumar Deshmukh; Teja Poosarla; Nicolette Paolaungthong Holliday; Donna Lynn Dyess; Ajay Pratap Singh; Seema Singh
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-08-19       Impact factor: 10.680

2.  Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling.

Authors:  Nehal Gupta; Sanjay K Srivastava
Journal:  Mol Cancer Ther       Date:  2019-07-03       Impact factor: 6.261

3.  Comprehensive Analysis Reveals USP45 as a Novel Putative Oncogene in Pan-Cancer.

Authors:  Kai Li; Qian Wang; Hua Bian; Zhiguo Chen; Haifa He; Xulin Zhao; Pengju Gong
Journal:  Front Mol Biosci       Date:  2022-06-28

4.  LncRNA LINC00460 takes a stimulating role on hepatocellular carcinoma stemness property.

Authors:  Bitao Chen; Kejun Zhang; Qinli Han; Weiwei Zhong; Jie Yi; Huiling Zhu; Shitao Xia
Journal:  Cell Cycle       Date:  2021-10-06       Impact factor: 5.173

5.  Three-dimensional single-cell imaging for the analysis of RNA and protein expression in intact tumour biopsies.

Authors:  Nobuyuki Tanaka; Shigeaki Kanatani; Dagmara Kaczynska; Keishiro Fukumoto; Lauri Louhivuori; Tomohiro Mizutani; Oded Kopper; Pauliina Kronqvist; Stephanie Robertson; Claes Lindh; Lorand Kis; Robin Pronk; Naoya Niwa; Kazuhiro Matsumoto; Mototsugu Oya; Ayako Miyakawa; Anna Falk; Johan Hartman; Cecilia Sahlgren; Hans Clevers; Per Uhlén
Journal:  Nat Biomed Eng       Date:  2020-06-29       Impact factor: 25.671

6.  Biophysical and epigenetic regulation of cancer stemness, invasiveness and immune action.

Authors:  Praveen Krishna Veerasubramanian; Annie Trinh; Navied Akhtar; Wendy F Liu; Timothy L Downing
Journal:  Curr Tissue Microenviron Rep       Date:  2020-11-02

Review 7.  Targeting cancer stem cells in drug discovery: Current state and future perspectives.

Authors:  Fang-Yu Du; Qi-Fan Zhou; Wen-Jiao Sun; Guo-Liang Chen
Journal:  World J Stem Cells       Date:  2019-07-26       Impact factor: 5.326

8.  Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells.

Authors:  Nehal Gupta; Shreyas Gaikwad; Itishree Kaushik; Stephen E Wright; Maciej M Markiewski; Sanjay K Srivastava
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 6.208

Review 9.  Drug rechanneling: A novel paradigm for cancer treatment.

Authors:  Itishree Kaushik; Sharavan Ramachandran; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2020-05-11       Impact factor: 15.707

10.  Atovaquone Suppresses the Growth of Metastatic Triple-Negative Breast Tumors in Lungs and Brain by Inhibiting Integrin/FAK Signaling Axis.

Authors:  Nehal Gupta; Sanjay K Srivastava
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.